Home / Business and Economy / Morepen Laboratories Sees 17% Profit Rise Despite 6% Sales Dip
Morepen Laboratories Sees 17% Profit Rise Despite 6% Sales Dip
15 Nov
Summary
- Net profit rose 17.27% to Rs 40.87 crore in Q3 2025
- Sales declined 5.97% to Rs 411.58 crore in Q3 2025
- Operating profit margin fell from 10.07% to 7.46%
In the third quarter of 2025, Morepen Laboratories, a leading pharmaceutical company, reported a mixed financial performance. The company's net profit rose by 17.27% to Rs 40.87 crore, compared to Rs 34.85 crore in the same quarter of the previous year. However, the company's sales declined by 5.97% to Rs 411.58 crore, down from Rs 437.73 crore in the third quarter of 2024.
The decline in sales led to a drop in the company's operating profit margin, which fell from 10.07% in the third quarter of 2024 to 7.46% in the current quarter. This indicates that the company faced challenges in maintaining its profitability despite the increase in net profit.
Despite the mixed financial performance, Morepen Laboratories has demonstrated its resilience in navigating the market challenges. The company's ability to maintain a healthy net profit growth in the face of declining sales suggests that it has implemented effective cost-control measures and diversified its product portfolio to mitigate the impact of the market downturn.
